Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer: Survival Benefit Varies by Setting
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Guan B, Chen Y, Zhou R, et al.
Oct 22, 2026 · Published in: Frontiers in Immunology
PD-1/PD-L1 inhibitors boost survival in triple-negative breast cancer.
Real-World Data Favor ARIs Over Abiraterone in Metastatic Hormone-Sensitive Prostate Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Gebrael G, Jo Y, Nandakumar V, et al.
Oct 20, 2026 · Published in: JAMA Network Open
Androgen receptor inhibitors show longer survival in prostate cancer.
Ivonescimab Plus Chemotherapy for Post-Escalation EGFR-Mutated NSCLC Leptomeningeal Metastases: Retrospective Signal
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Wu Q, Qiu L, An J, et al.
Oct 20, 2026 · Published in: Frontiers in Immunology
Exploring ivonescimab as salvage therapy for advanced NSCLC challenges.
One in Four Carboplatin Shortage Allocations Missed Policy Intent
★ Must Read Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Blackstone EC, Wang Y, Inyang EA, et al.
Oct 19, 2026 · Published in: JAMA Network Open
Also in Clinical Practice
Addressing chemotherapy shortages reveals critical allocation policy gaps.
Chemotherapy-Free Ponatinib-Blinatumomab Beats Imatinib-Chemotherapy in Adult Ph-Positive ALL
★ Editor's Pick Analysis Oncology Pharmacy Practice-changing Grade: Moderate
Chiaretti S, Piciocchi A, Skert C, et al.
Oct 14, 2026 · Published in: The New England Journal of Medicine
Chemotherapy-free regimen improves survival in Ph-positive ALL.
ARPI Intensification Raises Any-Grade Neutropenia Modestly, Not Severe Neutropenia
Analysis Oncology Pharmacy Confirmatory Grade: Low
Zhang J, Zhang A, Tian J, et al.
Oct 13, 2026 · Published in: BMC Cancer
ARPI intensification in prostate cancer modestly boosts neutropenia risk.
Perioperative chemoimmunotherapy improves survival in resectable gastric cancer
Analysis Oncology Pharmacy Confirmatory Grade: High
Chen Z, Liu X, Sun H, et al.
Oct 10, 2026 · Published in: Frontiers in Immunology
ICI plus chemotherapy boosts survival in gastric cancer treatment.
Adding Bevacizumab to Chemoimmunotherapy Extends PFS in Liver-Metastatic Lung Adenocarcinoma
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Li J, Ge Y, Liu Q, et al.
Oct 6, 2026 · Published in: Cancer Medicine
New treatments show promise for liver metastases in lung cancer.
Thymosin Alpha-1 Plus Chemotherapy in Gastric Cancer: Short-Term Gains, Weak Evidence
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wang Z, Sun T, Qu H, et al.
Oct 3, 2026 · Published in: Frontiers in Immunology
Thymosin alpha-1 boosts chemotherapy efficacy and safety in gastric cancer.
Chronic irAEs Persist in Nearly Half of Adjuvant Anti-PD-1 Melanoma Patients
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Kankaria RA, Fankhauser R, Boutros A, et al.
Oct 2, 2026 · Published in: JAMA Network Open
Chronic irAEs affect nearly half of melanoma patients on anti-PD-1 therapy.
Pharmacist Telemedicine Partially Offset Palliative Access Loss During Oncology Clinic Staffing Shortage
Analysis Palliative Care Hypothesis-generating Grade: Very Low
Cubbison C, Kematick B, Bacon M, et al.
Sep 30, 2026 · Published in: Journal of Pain and Symptom Management
Also in Oncology
Pharmacists drive telemedicine to bridge palliative care gaps.
Giredestrant Plus Everolimus Extends Post-CDK4/6 Inhibitor PFS, Driven by ESR1 Mutations
Analysis Oncology Pharmacy Practice-changing Grade: Moderate
Mayer EL, Tolaney SM, Martín M, et al.
Sep 30, 2026 · Published in: The New England Journal of Medicine
Giredestrant boosts outcomes in resistant breast cancer.
Metronomic Chemotherapy Extends PFS After CDK4/6 Inhibitor Progression
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Laini L, Cosentini D, Laganà M, et al.
Sep 30, 2026 · Published in: Cancer Medicine
Metronomic chemotherapy improves progression-free survival in difficult-to-treat breast cancer.
Targeting Leukemia Stem Cells to Expand Treatment-Free Remission in CML
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Dai J, Zheng P, Liu J, et al.
Sep 30, 2026 · Published in: Frontiers in Bioscience (Landmark Edition)
Novel therapies for CML aim to overcome resistance and improve remission.
Pharmacist Counseling Cuts Chemotherapy Admissions in Single-Center QI Study
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Assiri A, Median IA, Alshahrani K, et al.
Sep 29, 2026 · Published in: Journal of Research in Pharmacy Practice
Also in Clinical Practice
Pharmacist-led counseling slashes chemo admissions and boosts satisfaction.